CING
Cingulate Inc
NASDAQ: CING · HEALTHCARE · BIOTECHNOLOGY
$4.71
+0.64% today
Updated 2026-04-29
Market cap
$67.01M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.44
Dividend yield
—
52W range
$3 – $12
Volume
0.5M
Cingulate Inc (CING) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $178912.00 | $842353.00 | $808441.00 | $621993.00 | $582918.00 | $653090.00 | $540894.00 |
| Gross profit | $-178912.00 | $-842353.00 | $-808441.00 | $-621993.00 | $-582918.00 | $-653090.00 | $-540894.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $9.09M | $5.09M | $8.41M | $9.00M | $15.49M | $9.45M | $9.77M |
| SG&A | $2.30M | $1.99M | $12.27M | $8.51M | $7.27M | $6.20M | $10.16M |
| Operating income | $-11.65M | $-7.08M | $-20.68M | $-17.50M | $-22.76M | $-15.64M | $-19.94M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-11.37M | $-6.29M | $-19.87M | $-17.11M | $-22.95M | $-14.89M | $-19.40M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-11.55M | $-7.13M | $-20.68M | $-17.50M | $-23.53M | $-15.55M | $-19.94M |
| Interest expense | $0.00 | $54605.00 | $33407.00 | $174000.00 | $776000.00 | $99000.00 | $924446.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.55M | $-7.18M | $-20.74M | $-17.85M | $-23.53M | $-15.55M | $-22.45M |
| Net income growth (YoY) | — | +37.8% | -188.7% | +13.9% | -31.8% | +33.9% | -44.4% |
| Profit margin | — | — | — | — | — | — | — |